NasdaqGM:RLAYBiotechs
Relay Therapeutics Call Puts Zovegalisib Breast Cancer Prospects In Focus
Relay Therapeutics scheduled a special call to present new clinical data on its Zovegalisib triplet therapy in breast cancer.
The company plans to discuss the combination treatment results and their implications for its development programs.
The announcement focuses on Zovegalisib in a triplet regimen, which may be relevant for investors following Relay Therapeutics drug pipeline.
Relay Therapeutics, listed as NasdaqGM:RLAY, is drawing attention with a dedicated update on Zovegalisib, a key...